NLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech company providing the next-generation solution for biologic drug delivery as oral administration.
Anacura aquires Ohmx.bio
Latest NewsMerger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
Ten drug recommendations by EMA
Latest NewsEMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.
Nyxoah signs a €37.5m loan with the European Investment Bank
Latest NewsNyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with the European Investment Bank (“EIB”). The agreement is backed by the European Commission’s InvestEU program. Nyxoah plans to use the funding for research and development, and for scaling-up its manufacturing capacity to meet demand in Europe and the U.S.
Novo Nordisk expands footprint in USA
Latest NewsNovo Nordisk realises a major expansion in Clayton, NC (USA). The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space.
Forbion closes first Bioeconomy Fund with US$75m
Latest NewsForbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a sustainable supply of food and the rapid depletion of natural resources.
No more needles – Exvolvo arises with help of Verily and NLC Health
Latest NewsNLC Health Ventures (Amsterdam, The Netherlands), in partnership with Verily, the precision health technology daughter company of Alphabet/Google, will launch Exolvo Biosciences, a pioneering biotech company providing the next-generation solution for biologic drug delivery as oral administration.
Valneva gets approval for Chikungunya vaccine in Canada
Latest NewsValneva announces Health Canada approval of the world’s first chikungunya vaccine, IXCHIQ®.
Tubulis from Munich doses first Patient with own ADC linker technology
Latest NewsTubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models.
BIOSECURE Act could affect half of US biopharmaceutical development
Latest NewsThe BIOSECURE Act of the United States could affect more than 120 US biopharmaceutical drugs partnered with Chinese companies ‘of concern’, as named in the bill. Of these, approximately half are in clinical trials (phases I to III) and a third are in early preclinical and discovery stages, according to GlobalData, the analytics company.
Macomics expands leadership team
AppointmentsA new Chief Business Officer strengthens the management team of Macomics Ltd (UK). Simon Drew took over the newly created position in June.